Stay updated on Ruxolitinib vs BAT in Chronic GvHD Clinical Trial

Sign up to get notified when there's something new on the Ruxolitinib vs BAT in Chronic GvHD Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the Ruxolitinib vs BAT in Chronic GvHD Clinical Trial page

  1. Check
    6 days ago
    No Change Detected
  2. Check
    14 days ago
    Change Detected
    Summary
    The page now shows a new revision tag (v3.2.0) replacing the old one (v3.0.2), indicating a release upgrade with no other substantive content changes.
    Difference
    0.0%
    Check dated 2025-10-01T04:47:22.000Z thumbnail image
  3. Check
    15 days ago
    Change Detected
    Summary
    Updates the revision tag from v3.0.2 to v3.1.0, indicating a new release version without substantive changes to visible content.
    Difference
    0.0%
    Check dated 2025-09-30T03:20:14.000Z thumbnail image
  4. Check
    22 days ago
    Change Detected
    Summary
    Shift in page focus from Parkinson-associated proteins to oncogene/proto-oncogene protein families, altering core content and protein naming references.
    Difference
    0.4%
    Check dated 2025-09-22T23:43:15.000Z thumbnail image
  5. Check
    29 days ago
    Change Detected
    Summary
    Minor patch: version bumped from v3.0.1 to v3.0.2 and the 'Back to Top' link removed; no substantive changes to core content, pricing, stock, or time-slot information.
    Difference
    0.1%
    Check dated 2025-09-15T19:30:03.000Z thumbnail image
  6. Check
    36 days ago
    Change Detected
    Summary
    The page has been updated to reflect the final analysis of the Phase III REACH3 Study on Ruxolitinib, with a new publication date and revision number.
    Difference
    0.3%
    Check dated 2025-09-08T15:05:37.000Z thumbnail image
  7. Check
    43 days ago
    Change Detected
    Summary
    The webpage has been updated to include new facility names and locations, as well as additional drug information, particularly regarding Ruxolitinib and other treatments. Some previously listed locations and drug information have been removed.
    Difference
    12%
    Check dated 2025-09-01T09:41:34.000Z thumbnail image

Stay in the know with updates to Ruxolitinib vs BAT in Chronic GvHD Clinical Trial

Enter your email address, and we'll notify you when there's something new on the Ruxolitinib vs BAT in Chronic GvHD Clinical Trial page.